Gemtuzumab Ozogamicin (Mylotarg) as a single agent for moleculary relapsed acute promyelocytic leukemia

MLA

Adriano Venditti, et al. Gemtuzumab Ozogamicin (Mylotarg) as a Single Agent for Moleculary Relapsed Acute Promyelocytic Leukemia. Jan. 2004. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d18fe42c61863493c76f92cb3288267f&authtype=sso&custid=ns315887.

APA

Adriano Venditti, Erica Finolezzi, Mariagrazia Kropp, Massimo Breccia, Agostino Tafuri, Daniela Diverio, Franco Mandelli, Eros Di Bona, Concetta Micalizzi, Nélida I. Noguera, Francesco Lo-Coco, Giuseppe Cimino, & Enrico Pogliani. (2004). Gemtuzumab Ozogamicin (Mylotarg) as a single agent for moleculary relapsed acute promyelocytic leukemia.

Chicago

Adriano Venditti, Erica Finolezzi, Mariagrazia Kropp, Massimo Breccia, Agostino Tafuri, Daniela Diverio, Franco Mandelli, et al. 2004. “Gemtuzumab Ozogamicin (Mylotarg) as a Single Agent for Moleculary Relapsed Acute Promyelocytic Leukemia,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d18fe42c61863493c76f92cb3288267f&authtype=sso&custid=ns315887.